Christel Fontaine - Concepedia

Author

Christel Fontaine

Universitair Ziekenhuis Brussel ORCID

Also Known As

C Fontaine, C J Fontaine, C. Fontaine, CHRISTEL FONTAINE, Christel Fontaine, Fontaine, C., Fontaine, Christel

160

Publications

2.1K

Citations

H-Index

Concepts

All Affiliations

Universitair Ziekenhuis Brussel Vrije Universiteit Brussel KU Leuven Institut Jules Bordet Cliniques Universitaires Saint-Luc

About

Christel Fontaine is an author at Universitair Ziekenhuis Brussel specializing in medicine, oncology, and breast cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	19	885
2	Health Sciences	5	5	197
3	Public Health	2	2	27
4	Engineering	1	1	32
5	Cardiothoracic Surgery	1	1	15

Christel Fontaine

Publications

1.9K

Citations

H-Index

Page 1

	Year	Citations
Phase I Study of <sup>68</sup>Ga-HER2-Nanobody for PET/CT Assessment of HER2 Expression in Breast Carcinoma Marleen Keyaerts, Catarina Xavier, Johannes Heemskerk, Journal of Nuclear Medicine	2015	419
Catheter tip position as a risk factor for thrombosis associated with the use of subcutaneous infusion ports Jo Caers, Christel Fontaine, Vincent Vinh‐Hung, Supportive Care in Cancer Pulmonary EmbolismThrombosisVenous ThrombosisPatient SafetyVascular Surgery	2004	177
The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: Results of a phase I study with pharmacokinetics Ahmad Awada, Fátima Cardoso, Christel Fontaine, European Journal of Cancer Advanced Breast CancerBreast OncologyOncologyMedicineBreast Cancer	2007	152
Phase I Trial of <sup>131</sup>I-GMIB-Anti-HER2-VHH1, a New Promising Candidate for HER2-Targeted Radionuclide Therapy in Breast Cancer Patients Matthias D’Huyvetter, Jens De Vos, Vicky Caveliers, Journal of Nuclear Medicine Breast OncologyHealthy SubjectsTumor BiologyRadiation MedicineBreast Cancer Patients	2020	116
Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI) Patrick Schöffski, Jean‐Yves Blay, Jacques De Grève, European Journal of Cancer OncologyMedicinePathologyImmune Checkpoint InhibitorBreast Cancer	2010	109
Epirubicin Plus Tamoxifen Versus Tamoxifen Alone in Node-Positive Postmenopausal Patients With Breast Cancer: A Randomized Trial of the International Collaborative Cancer Group J. Wils, Judith M. Bliss, M. Marty, Journal of Clinical Oncology	1999	82
Impact of solid cancer on in-hospital mortality overall and among different subgroups of patients with COVID-19: a nationwide, population-based analysis Evandro de Azambuja, Mariana Brandão, Hans Wildiers, ESMO Open	2020	73
Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer—phase 3 ASCENT study subanalysis Lisa A. Carey, Delphine Loirat, Kevin Punie, npj Breast Cancer	2022	62
Tolerance of adjuvant letrozole outside of clinical trials Christel Fontaine, Ann Meulemans, Manon Huizing, The Breast Breast OncologyOncologyStandard CareMetronomic TherapyPharmacology	2008	52
Identification of candidate cancer predisposing variants by performing whole-exome sequencing on index patients from BRCA1 and BRCA2-negative breast cancer families Rajendra Bahadur Shahi, Sylvia De Brakeleer, Ben Caljon, BMC Cancer	2019	49

Page 1